Novaliq GmbH announces licensing agreement with AFT pharmaceuticals for the distribution of NovaTears®

Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (AFT) for the commercialization of Novaliq’s lead product NovaTears® in Australia and New Zealand. NovaTears is Novaliq’s first commercially available ophthalmic product for the treatment…